RU2324484C2 - Антагонисты метаботропного глутаматного рецептора 5 (mglur5) и способ для профилактики и лечения гастроэзофагеальной рефлюксной болезни (варианты) - Google Patents

Антагонисты метаботропного глутаматного рецептора 5 (mglur5) и способ для профилактики и лечения гастроэзофагеальной рефлюксной болезни (варианты) Download PDF

Info

Publication number
RU2324484C2
RU2324484C2 RU2005101411/15A RU2005101411A RU2324484C2 RU 2324484 C2 RU2324484 C2 RU 2324484C2 RU 2005101411/15 A RU2005101411/15 A RU 2005101411/15A RU 2005101411 A RU2005101411 A RU 2005101411A RU 2324484 C2 RU2324484 C2 RU 2324484C2
Authority
RU
Russia
Prior art keywords
glutamate receptor
metabotropic glutamate
gastroesophageal reflux
treatment
antagonist
Prior art date
Application number
RU2005101411/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2005101411A (ru
Inventor
Андерс ЛЕХМАН (SE)
Андерс ЛЕХМАН
Ян МАТСОН (SE)
Ян МАТСОН
Томас М. СТОРМЭН (US)
Томас М. СТОРМЭН
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20288301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2324484(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU2005101411A publication Critical patent/RU2005101411A/ru
Application granted granted Critical
Publication of RU2324484C2 publication Critical patent/RU2324484C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2005101411/15A 2002-06-20 2003-06-19 Антагонисты метаботропного глутаматного рецептора 5 (mglur5) и способ для профилактики и лечения гастроэзофагеальной рефлюксной болезни (варианты) RU2324484C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201943-8 2002-06-20
SE0201943A SE0201943D0 (sv) 2002-06-20 2002-06-20 New use

Publications (2)

Publication Number Publication Date
RU2005101411A RU2005101411A (ru) 2005-07-10
RU2324484C2 true RU2324484C2 (ru) 2008-05-20

Family

ID=20288301

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005101411/15A RU2324484C2 (ru) 2002-06-20 2003-06-19 Антагонисты метаботропного глутаматного рецептора 5 (mglur5) и способ для профилактики и лечения гастроэзофагеальной рефлюксной болезни (варианты)

Country Status (24)

Country Link
EP (1) EP1513525B1 (enExample)
JP (2) JP4683920B2 (enExample)
CN (1) CN100430056C (enExample)
AT (1) ATE395059T1 (enExample)
AU (1) AU2003241585B2 (enExample)
BR (1) BR0311759A (enExample)
CA (1) CA2489730C (enExample)
CY (1) CY1107954T1 (enExample)
DE (1) DE60320990D1 (enExample)
DK (1) DK1513525T3 (enExample)
ES (1) ES2304510T3 (enExample)
IL (1) IL165138A0 (enExample)
IS (1) IS7654A (enExample)
MX (1) MXPA04012659A (enExample)
NO (1) NO20050154L (enExample)
NZ (1) NZ536559A (enExample)
PL (1) PL372186A1 (enExample)
PT (1) PT1513525E (enExample)
RU (1) RU2324484C2 (enExample)
SE (1) SE0201943D0 (enExample)
SI (1) SI1513525T1 (enExample)
UA (1) UA81627C2 (enExample)
WO (1) WO2004000316A1 (enExample)
ZA (1) ZA200409908B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
SE0303418D0 (sv) * 2003-12-17 2003-12-17 Astrazeneca Ab New use 1
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
WO2005060961A2 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
WO2005077368A2 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
AU2005214378A1 (en) * 2004-02-18 2005-09-01 Astrazeneca Ab Polyheterocyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1716130A1 (en) * 2004-02-18 2006-11-02 AstraZeneca AB Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists
GB0514296D0 (en) * 2005-07-12 2005-08-17 Novartis Ag Organic compounds
JP5249919B2 (ja) * 2006-03-29 2013-07-31 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕＲ２アンタゴニストとしてのピリジン及びピリミジン誘導体
EP2272509A1 (en) 2006-09-11 2011-01-12 Novartis AG New Uses of metabotropic glutamate receptors
JP2008245225A (ja) * 2007-03-29 2008-10-09 Kddi Corp 波長パス経路決定装置、波長パス設定制御システム及びプログラム
WO2009024491A1 (en) * 2007-08-20 2009-02-26 F. Hoffmann-La Roche Ag Use of mglur5 antagonists for the treatment of gerd
MX2010014222A (es) 2008-06-30 2011-03-29 Novartis Ag Star Combinaciones que comprenden moduladores de mglur para el tratamiento de enfermedad de parkinson.
JP2012533601A (ja) 2009-07-23 2012-12-27 ノバルティス アーゲー 運動失調症の処置または予防のための、アザビシクロアルキル誘導体またはピロリジン−２−オン誘導体の使用
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
EP2490691A1 (en) 2009-10-20 2012-08-29 Novartis AG Use of 1h-quinazoline-2,4-diones
RU2013103001A (ru) 2010-06-24 2014-07-27 Новартис Аг Применение 1н-хиназолин-2,4-дионов
US20140171448A1 (en) 2011-01-27 2014-06-19 Novartis Ag Use of nicotinic acetylcholine receptor alpha 7 activators
MX2014002693A (es) 2011-09-07 2014-06-04 Novartis Ag Uso de 1h-quinazolina-2,4-dionas para usarse en la prevencion o el tratamiento de epilepsia fotosensible.
CA2898043C (en) 2013-01-15 2019-08-06 Novartis Ag Use of alpha 7 nicotinic receptor agonists for the treatment of narcolepsy
KR101879919B1 (ko) 2013-01-15 2018-07-18 노파르티스 아게 알파 7 니코틴성 아세틸콜린 수용체 작용물질의 용도
US20220387410A1 (en) * 2019-11-05 2022-12-08 Claes Thulin 4-[5-[(rac)-1-[5-(3-Chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4H-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of surmenage in a mammal

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2144331C1 (ru) * 1998-11-05 2000-01-20 Московский НИИ уха, горла и носа Способ лечения хронического гиперпластического ларингита
US6117908A (en) * 1996-09-18 2000-09-12 Astra Aktiebolag Use of GABAB receptor agonists as reflux inhibitors
WO2001012627A1 (en) * 1999-08-19 2001-02-22 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2002028837A1 (en) * 2000-10-02 2002-04-11 Janssen Pharmaceutica N.V. Metabotropic glutamate receptor antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0250572A1 (en) * 1986-01-03 1988-01-07 The University Of Melbourne Gastro-oesophageal reflux composition
AU758955C (en) * 1998-05-15 2004-09-30 Cancer Advances, Inc. Method for the treatment of gastroesophageal reflux disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117908A (en) * 1996-09-18 2000-09-12 Astra Aktiebolag Use of GABAB receptor agonists as reflux inhibitors
RU2144331C1 (ru) * 1998-11-05 2000-01-20 Московский НИИ уха, горла и носа Способ лечения хронического гиперпластического ларингита
WO2001012627A1 (en) * 1999-08-19 2001-02-22 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2002028837A1 (en) * 2000-10-02 2002-04-11 Janssen Pharmaceutica N.V. Metabotropic glutamate receptor antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
реферат Entrez PubMed Walker К. et al. Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function. I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain. Neuropharmacology. 2001; 40(1):1-9 [on-line] PMID: 11077065 [найдено 08.02.2007]. КОН P.M. и др. Ранняя диагностика болезней обмена веществ. - М.: Медицина, 1986, с.206-210. *
Энциклопедия лекарств. - М.: РЛС, 2001, с.1288, 1289, 1296, 1297. *

Also Published As

Publication number Publication date
ES2304510T3 (es) 2008-10-16
ATE395059T1 (de) 2008-05-15
CN1662235A (zh) 2005-08-31
NZ536559A (en) 2007-08-31
AU2003241585B2 (en) 2009-06-25
EP1513525A1 (en) 2005-03-16
JP2011068669A (ja) 2011-04-07
RU2005101411A (ru) 2005-07-10
SI1513525T1 (sl) 2008-08-31
PL372186A1 (en) 2005-07-11
CA2489730C (en) 2011-11-22
CY1107954T1 (el) 2013-09-04
AU2003241585A1 (en) 2004-01-06
BR0311759A (pt) 2005-03-08
ZA200409908B (en) 2006-08-30
CN100430056C (zh) 2008-11-05
DK1513525T3 (da) 2008-08-11
JP4683920B2 (ja) 2011-05-18
DE60320990D1 (de) 2008-06-26
IS7654A (is) 2005-01-19
WO2004000316A1 (en) 2003-12-31
PT1513525E (pt) 2008-06-24
HK1075833A1 (en) 2005-12-30
NO20050154L (no) 2005-01-11
IL165138A0 (en) 2005-12-18
EP1513525B1 (en) 2008-05-14
JP2006507225A (ja) 2006-03-02
UA81627C2 (ru) 2008-01-25
SE0201943D0 (sv) 2002-06-20
MXPA04012659A (es) 2006-05-25
CA2489730A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
CN100430056C (zh) Mglur5拮抗剂在制备治疗gerd的药物中的用途
BRPI0716234A2 (pt) Composição farmacêutica compreendendo uma série de minicomprimidos compreendendo um inibidor do fator xa
JP4048024B2 (ja) 新規経口製剤
CA3038875A1 (en) Treatment of prostate cancer
JPWO2013081154A1 (ja) キナーゼ阻害剤の副作用低減剤
KR20010041110A (ko) 트라마돌을 함유하는 약제학적 배합물
JP2025027020A (ja) 患者において血清リン酸塩を低下させるための組み合わせ
JP2007533759A (ja) 肺高血圧症の治療及び管理のためのサリドマイドを含む組成物及びその使用方法
EA007952B1 (ru) Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии
JP2005511632A (ja) 胃食道逆流疾患の治療のための新しい使用
EP1872795A1 (en) Therapeutic agent for irritable bowel syndrome
JP2002523363A (ja) 慢性疲労症候群および／または線維筋痛の処置のためのサブスタンスｐアンタゴニストの使用および慢性疲労症候群の処置のためのｎｋ−１レセプターアンタゴニストの使用
JPWO2006118212A1 (ja) 膵炎の予防および治療剤
CN101316586A (zh) 5-ht4激动剂用于治疗可以由质子泵抑制剂诱导的胃排空延迟的用途
JP2024518426A (ja) 投与レジメン
AU2002328569B2 (en) Medicinal compositions containing angiotensin II receptor antagonist
US7964609B2 (en) Use of mGluR5 antagonists for the treatment of gerd
KR20050024351A (ko) Ｇｅｒｄ 치료용 ｍｇｌｕｒ５ 길항제의 용도
KR20150036115A (ko) 위식도 역류증에 대한 약제
US7842702B2 (en) Treatment for irritable bowel syndrome
TW202440089A (zh) 用於治療間質性肺病之lpa1拮抗劑
JP2000355551A (ja) 医薬組成物
HK1075833B (en) Use of mglur5 antagonists for the treatment of gerd
HK40096733A (zh) 步态障碍治疗剂
WO2005058361A1 (en) USE OF mGluR1 ANTAGONISTS FOR THE TREATMENT OF GERD

Legal Events

Date Code Title Description
TK4A Correction to the publication in the bulletin (patent)

Free format text: AMENDMENT TO CHAPTER -FG4A- IN JOURNAL: 14-2008

MM4A The patent is invalid due to non-payment of fees

Effective date: 20120620